A5035735295- Radiopharmaceutical Chemistry and Applications
- Medical Imaging Techniques and Applications
- Monoclonal and Polyclonal Antibodies Research
- Radioactive Decay and Measurement Techniques
- Click Chemistry and Applications
- Advanced biosensing and bioanalysis techniques
- Chemical Synthesis and Characterization
- Radioactive element chemistry and processing
- Cancer Research and Treatments
- Lymphoma Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
University of Gothenburg
2023-2025
To enhance targeting efficacy in the radioimmunotherapy of disseminated cancer, several pretargeting strategies have been developed. In pretargeted radioimmunotherapy, tumor is with a modified monoclonal antibody that has an affinity for both antigens and radiolabeled carriers. this work, we aimed to synthesize evaluate poly-L-lysine-based effector molecules applications based on tetrazine trans-cyclooctene reaction using 211At targeted alpha therapy 125I as surrogate imaging radionuclides...
Abstract Background A significant challenge in cancer therapy lies eradicating hidden disseminated tumor cells. Within Nuclear Medicine, Targeted Alpha Therapy is a promising approach for treatment tackling cancer. As size decreases, alpha-particles gain prominence due to their high Linear Energy Transfer (LET) and short path length. Among alpha-particle emitters, 211 At stands out with its 7.2 hour half-life 100% alpha emission decay. However, optimizing the pharmacokinetics of...
Abstract Targeted alpha therapy of disseminated cancer is an emerging technique where astatine-211 one the most promising candidate nuclides. Astatine-211 can be produced in medium energy cyclotrons by particle bombardment natural bismuth. The astatine then commonly recovered from irradiated solid target material through dry distillation. distillation process often includes elution and solvation condensed with chloroform, forming Chloroform Eluate. In this work handling safe use high...
Abstract Background Pretargeted radioimmunotherapy of cancer has the potential to increase tumor specific uptake activity when compared with conventional radioimmunotherapy. This is especially true in nuclides that exhibit a relatively short half-life. When administering antibody-based pretargeting molecules systemically, antibodies often show slow clearance from blood. Therefore, use clearing agent advantageous remove unbound circulation, facilitating reduction nonspecific radiation...